Opportunity Information: Apply for RFA NS 22 032
The Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection - Interventions (RFA-NS-22-032) is an NIH/NINDS funding opportunity built to move promising stroke-protection treatments through a more disciplined, head-to-head preclinical testing pipeline. The central idea is to take cerebroprotective drugs or other interventions that already have strong supporting evidence and evaluate them in a standardized, networked way that better predicts whether they are worth advancing toward major clinical trials. This award uses the U01 cooperative agreement mechanism, which means the funded teams do their science in close coordination with NINDS and the broader SPAN infrastructure rather than operating as fully independent, stand-alone projects. Clinical trials are not allowed under this announcement; the work is strictly preclinical and translational.
The research focus is acute ischemic stroke, specifically interventions intended to protect the brain when given before reperfusion or right at the time reperfusion occurs. In real-world stroke care, reperfusion refers to restoring blood flow, often through clot-busting drugs or mechanical thrombectomy. SPAN is targeting the gap where many neuroprotective approaches have looked encouraging in small or variable animal studies but have not held up when scaled, standardized, or pushed toward clinical translation. The FOA emphasizes experimental ischemic stroke models such as transient middle cerebral artery occlusion (tMCAo), reflecting a goal of testing treatments under conditions that mimic key features of human ischemic stroke and reperfusion injury.
A defining feature of SPAN is that it is a coordinated network designed to test multiple candidate interventions in parallel. The program plans to support testing for up to eight cerebroprotective drugs or interventions. Rather than each applicant running an isolated set of experiments, successful applicants become "intervention contributors" within SPAN and work alongside a SPAN Coordinating Center and designated testing laboratories funded through companion FOAs. This structure is meant to improve rigor, reproducibility, and comparability across interventions by using shared protocols, common outcome measures, and coordinated study execution. It also helps reduce the time and cost typically required to generate the kind of robust preclinical package needed to justify pivotal clinical development.
Applicants are expected to bring a clearly defined, promising cerebroprotective intervention that is ready for network-level validation. A key requirement is rigorous and extensive preliminary data, meaning the intervention should not be a speculative early-stage concept. The expectation is that the candidate has already demonstrated convincing effects in relevant preclinical contexts and is now prepared for more definitive, standardized testing that can confirm the signal and clarify how reliable and translatable it may be. In practical terms, SPAN is positioned as a gatekeeping and acceleration step: candidates that perform well in this tougher, harmonized setting are better positioned for future clinical trial planning, while those that fail can be deprioritized earlier, saving resources.
The collaboration requirements are central to the opportunity. Awardees are not only funded to provide their intervention and participate scientifically, but also to coordinate with the SPAN Coordinating Center (referenced as RFA-NS-22-004), the SPAN testing laboratories (RFA-NS-22-003), and other funded intervention contributors (including related FOAs such as RFA-NS-22-033). This networked approach is specifically intended to "span the gap" between small businesses, academic or other preclinical testing labs, and a credible pipeline toward clinical testing. It is also meant to address longstanding concerns in the stroke field about inconsistent preclinical methods and the difficulty of selecting the best candidates for expensive late-stage clinical trials.
In terms of eligibility, the FOA is broadly open to many U.S.-based organizational types, including state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments; tribal organizations; nonprofits (with or without 501(c)(3) status); public housing authorities/Indian housing authorities; for-profit organizations (including but not limited to small businesses); and other applicant categories listed by NIH. The announcement also explicitly highlights various mission-driven and capacity-building institution types as eligible, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian serving institutions, among others. At the same time, the FOA draws a firm boundary around foreign involvement: non-U.S. (foreign) entities are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components as defined by NIH policy are not allowed.
Administrative details from the source listing include that the sponsor is the National Institutes of Health, the activity falls under the health category, and the CFDA number associated with NINDS is 93.853. The opportunity uses a discretionary funding category and the cooperative agreement instrument (U01). The original closing date shown in the source is March 14, 2022, and the opportunity was created January 6, 2022. While the source text does not provide an award ceiling or an expected number of awards in the fields shown, the program description indicates the intention to support testing of up to eight interventions through the SPAN network.
Overall, this FOA is aimed at applicants who already have a strong cerebroprotective candidate and want it evaluated through a highly structured, multi-site, coordinated preclinical testing framework. The program is designed to deliver a clearer, faster answer to a hard question in stroke research: which acute cerebroprotective interventions truly deserve to move forward into the high-stakes world of pivotal clinical trials.Apply for RFA NS 22 032
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies For Acute Cerebroprotection- Interventions (U01 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.853.
- This funding opportunity was created on 2022-01-06.
- Applicants must submit their applications by 2022-03-14. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the Stroke Preclinical Assessment Network (SPAN) funding opportunity (RFA-NS-22-032)?
RFA-NS-22-032 is an NIH/NINDS funding opportunity that supports preclinical and translational testing of promising acute stroke cerebroprotective interventions. The goal is to move strong candidate treatments through a disciplined, standardized, head-to-head preclinical testing pipeline that better predicts whether an intervention is worth advancing toward major clinical trials.
What is the main purpose of SPAN?
SPAN is designed to improve rigor, reproducibility, and comparability in preclinical stroke research by testing multiple candidate interventions in parallel using shared protocols, common outcome measures, and coordinated execution across a network. It aims to help identify which interventions are truly robust and translatable before major resources are committed to late-stage clinical development.
What type of stroke is the FOA focused on?
The FOA focuses on acute ischemic stroke and interventions intended to protect the brain when given before reperfusion or at the time reperfusion occurs.
What does "reperfusion" mean in this context?
In real-world stroke care, reperfusion refers to restoring blood flow, often through clot-busting drugs or mechanical thrombectomy. SPAN targets cerebroprotective interventions relevant to this period, including the time just before or right as reperfusion happens.
Are clinical trials allowed under this funding opportunity?
No. Clinical trials are not allowed under this announcement. The work supported by this FOA is strictly preclinical and translational.
What kind of interventions are appropriate for SPAN?
The FOA is intended for cerebroprotective drugs or other interventions that already have strong supporting evidence and are ready for rigorous network-level validation. The intervention should not be a speculative, early-stage concept.
What does SPAN mean by "rigorous and extensive preliminary data"?
Based on the FOA description, applicants are expected to bring convincing preclinical evidence showing the intervention has meaningful effects in relevant contexts. The intervention should be mature enough to justify more definitive, standardized testing across a coordinated network.
What experimental models does SPAN emphasize?
The FOA emphasizes experimental ischemic stroke models such as transient middle cerebral artery occlusion (tMCAo), reflecting a goal of testing interventions under conditions that mimic key features of human ischemic stroke and reperfusion injury.
How is SPAN structured?
SPAN is a coordinated network that includes intervention contributors (funded under this FOA), a SPAN Coordinating Center (referenced as RFA-NS-22-004), and designated SPAN testing laboratories (referenced as RFA-NS-22-003). The network is designed so candidates can be tested in a standardized, comparable way rather than through isolated experiments.
What is meant by "intervention contributors"?
Successful applicants to RFA-NS-22-032 become intervention contributors within SPAN. They provide a clearly defined candidate intervention and participate scientifically while coordinating with the SPAN Coordinating Center, SPAN testing laboratories, and other funded intervention contributors.
How many interventions does SPAN plan to test?
The program description indicates an intention to support testing for up to eight cerebroprotective drugs or interventions through the SPAN network.
What funding mechanism is used for this opportunity?
This FOA uses the U01 cooperative agreement mechanism. Under a cooperative agreement, funded teams do their work in close coordination with NINDS and the broader SPAN infrastructure rather than operating as fully independent, stand-alone projects.
What does it mean that this is a cooperative agreement (U01)?
It means the project is expected to be carried out with substantial coordination and collaboration involving NINDS and the SPAN network components. The funded effort is designed to align with shared network protocols and coordinated study execution.
What problem in stroke research is SPAN trying to address?
SPAN targets the gap where many neuroprotective approaches have appeared promising in small or variable animal studies but have not held up when scaled, standardized, or advanced toward clinical translation. The network approach is intended to reduce inconsistent methods and improve selection of the best candidates for expensive late-stage clinical trials.
How does SPAN help with translation toward human studies if clinical trials are not allowed?
SPAN is positioned as a gatekeeping and acceleration step. Interventions that perform well under SPAN's tougher, harmonized preclinical testing conditions are better positioned for future clinical trial planning, while weaker candidates can be deprioritized earlier to save time and resources.
Who is the sponsor of this funding opportunity?
The sponsor is the National Institutes of Health (NIH), specifically the National Institute of Neurological Disorders and Stroke (NINDS).
What is the associated CFDA number?
The CFDA number associated with NINDS for this opportunity is 93.853.
What organizations are eligible to apply?
Eligibility is broadly open to many U.S.-based organizational types, including state, county, and local governments; public and private institutions of higher education; federally recognized tribal governments; tribal organizations; nonprofits (with or without 501(c)(3) status); public housing authorities/Indian housing authorities; and for-profit organizations (including small businesses), along with other applicant categories listed by NIH.
Are mission-driven and capacity-building institutions eligible?
Yes. The FOA explicitly highlights eligibility for institutions such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), and Alaska Native and Native Hawaiian serving institutions, among others.
Are foreign organizations eligible to apply?
No. Non-U.S. (foreign) entities are not eligible to apply under this FOA.
Can a U.S. organization include a non-U.S. (non-domestic) component?
No. Non-domestic components of U.S. organizations are not eligible under this announcement.
Are foreign components allowed under NIH policy for this FOA?
No. The FOA states that foreign components (as defined by NIH policy) are not allowed.
What is the activity category and funding category indicated in the listing?
The source listing places the opportunity in the health category and indicates a discretionary funding category.
What was the original closing date shown in the source listing?
The original closing date shown is March 14, 2022.
When was the opportunity created, according to the source?
The source states the opportunity was created on January 6, 2022.
Does the provided information list an award ceiling or the expected number of awards?
No award ceiling or expected number of awards is provided in the fields shown in the source listing. However, the program description indicates an intention to support testing of up to eight interventions through the SPAN network.
How does SPAN differ from an applicant running an independent preclinical project?
Rather than funding isolated experiments, SPAN integrates awardees into a coordinated network that uses shared protocols and coordinated study execution. The intent is to make results more comparable across interventions and more predictive of whether a candidate should advance toward clinical trials.
What collaborations are expected from awardees?
Awardees are expected to coordinate with the SPAN Coordinating Center (RFA-NS-22-004), the SPAN testing laboratories (RFA-NS-22-003), and other funded intervention contributors, including related FOAs such as RFA-NS-22-033.
What stage of development is this FOA best suited for?
This FOA is best suited for applicants who already have a strong, clearly defined cerebroprotective candidate with extensive supporting preclinical evidence and want it evaluated through a structured, multi-site, coordinated testing framework designed to clarify robustness and translational potential.
Browse more opportunities from the same category: Health
Next opportunity: OVW Fiscal Year 2022 Grants to Tribal Governments to Exercise Special Domestic Violence Criminal Jurisdiction Solicitation
Previous opportunity: Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA NS 22 032
Applicants also applied for:
Applicants who have applied for this opportunity (RFA NS 22 032) also looked into and applied for these:
| Funding Opportunity |
|---|
| Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection- Interventions from Small Businesses (U44 Clinical Trial Not Allowed) Apply for RFA NS 22 033 Funding Number: RFA NS 22 033 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Physician Scientist Transition to Independence in Blood Science Research (R00 - Clinical Trial Optional) Apply for RFA HL 23 003 Funding Number: RFA HL 23 003 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Limited Competition: Stroke Preclinical Assessment Network (SPAN) to Support Translational Studies for Acute Cerebroprotection - Coordinating Center (U24 Clinical Trial Not Allowed) Apply for RFA NS 22 004 Funding Number: RFA NS 22 004 Agency: National Institutes of Health Category: Health Funding Amount: $600,000 |
| Host Immunity and Novel Immunization Strategies for Clostridioides difficile Infection (CDI) (U19 Clinical Trial Not Allowed) Apply for RFA AI 22 001 Funding Number: RFA AI 22 001 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| NIA Renewal and Competing Revision Cooperative Agreements in Aging Research (U01 Clinical Trial Optional) Apply for PAR 22 362 Funding Number: PAR 22 362 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Basic Instrumentation Grant (BIG) Program (S10 Clinical Trial Not Allowed) Apply for PAR 22 081 Funding Number: PAR 22 081 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed) Apply for PAR 22 080 Funding Number: PAR 22 080 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed) Apply for PAR 22 079 Funding Number: PAR 22 079 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot Studies for the Spectrum of Alzheimers Disease/Alzheimers Disease-Related Dementias and Age-Related Cognitive Decline (R61 Clinical Trial Optional) Apply for PAR 21 360 Funding Number: PAR 21 360 Agency: National Institutes of Health Category: Health Funding Amount: $325,000 |
| Early and Late Stage Clinical Trials for the Spectrum of Alzheimers Disease/Alzheimers Related Dementias and Age-Related Cognitive Decline (R01 Clinical Trial Optional) Apply for PAR 21 359 Funding Number: PAR 21 359 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| HEAL Initiative: Restoring Joint Health and Function to Reduce Pain Consortium (RE-JOIN) (UC2 Clinical Trial Not Allowed) Apply for RFA AR 22 009 Funding Number: RFA AR 22 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Basic Experimental Studies Involving Humans Required) Apply for PAR 22 043 Funding Number: PAR 22 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Not Allowed) Apply for PAR 22 041 Funding Number: PAR 22 041 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Not Allowed) Apply for PAR 22 044 Funding Number: PAR 22 044 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Basic Experimental Studies Involving Humans Required) Apply for PAR 22 046 Funding Number: PAR 22 046 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Dentist Scientist Career Transition Award for Intramural Investigators (K22 Clinical Trial Required) Apply for PAR 22 045 Funding Number: PAR 22 045 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCR Dual Degree Dentist Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required) Apply for PAR 22 042 Funding Number: PAR 22 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| USAID Malaria Capacity Strengthening (MCAPS) in Mozambique Apply for 72065622RFA00004 Funding Number: 72065622RFA00004 Agency: Mozambique USAID-Maputo Category: Health Funding Amount: $29,900,000 |
| Nonhuman Primate Transplantation Tolerance Cooperative Study Group (U01 Clinical Trial Not Allowed) Apply for RFA AI 22 002 Funding Number: RFA AI 22 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Scalable and Systematic Neurobiology of Psychiatric and Neurodevelopmental Disorder Risk Genes: Data Resource and Administrative Coordination Center (U24 Clinical Trial Not Allowed) Apply for RFA MH 22 110 Funding Number: RFA MH 22 110 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA NS 22 032", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.